Jump to content
Sign in to follow this  
drbubb

Experion / EXP: & other Marijuana stocks

Recommended Posts

Experion / EXP: & other Marijuana stocks

original:

Viridium Pacific Ltd - VIR.v /was MRB.v : Marijuana Labs

(here's the future for an almost-dead mining exploration company, whose shares I held)

Morro Bay Resources Ltd > Viridium Pacific Ltd ... with reverse split coming...

"a reverse take-over of Morro Bay by Experion"

Morro Bay Resources Ltd WAS engaged in gold-silver exploration with mineral interests in the Penoles Project in Mexico.

The Company has operations in Penoles, Mexico."

 

VIR / Viridium Pacific / MRB : Morro Bay. ... all-data : 5-yr : 2-yr : 12mo ::

8/4/2017 : lo:$0.05 - hi:C$0.25: $0,902 / x 3,606 = $0,541 @ C$0.15

rQdJhs7.gif

SPLITS:

Morro Bay / VIR – Split 10-1 in May, then 3.603 for one last week (10/12)

shs os: 9,180,096 : 100.% x C$ 0.15 = C$ 1.37 million

other : 0,482,998 : 5.26% : John Zang

Reverse Takeover Transaction coming:

0. starting shares outstanding : 09,180,096

1. issue shares for debts------ : 02,781,094

=========

Shs OS prior consolidation : 11, 961,290

Shs OS after consolidation : 2,903,618 : at a rate of: 1 / 4.119443 :: $0.15 x 4.119= C$ 0.61785

2. issue to Experion ------------ : 41,767,086 - post consolidation shs, to own 93.5%

Total shs OS, post-consol. : 44,670,704 : x C$0.618 = C$ 27.6 million.

Calgary, Alberta (FSCwire) - Morro Bay Resources Ltd. (“Morro Bay” or the “Company”) (TSXV: MRB, OTCPink: MRRBF) is pleased to provide an update and additional information in regard to the proposed reverse takeover transaction announced by Morro Bay on May 23, 2017 (the “Transaction”).

Update on the Transaction

As announced on May 23, 2017, Morro Bay has made an offer to acquire all of the outstanding shares of a private company located in British Columbia (the “Offer”). The private company’s name is Experion Biotechnologies Inc. (“Experion”). As previously announced, the Offer was made on May 15, 2017, and is open for acceptance by the Experion shareholders within thirty (30) days after delivery (therefore being approximately June 16, 2017) unless otherwise extended by Morro Bay. Pursuant to the Offer, Morro Bay has offered to issue to the Experion shareholders 205,500,000 Morro Bay common shares in exchange for all of the issued and outstanding shares of Experion. The deemed value per share is $0.1217 per Morro Bay Share (the total deemed value is approximately $25 million). The delivery of 205,500,000 Morro Bay common shares will result in the Experion shareholders owning approximately 93% of Morro Bay’s common shares...

Additional information concerning the Offer is contained in the News Release dated May 23, 2017.

Read more at http://www.stockhouse.com/news/press-releases/2017/06/07/morro-bay-resources-ltd-provides-further-details-on-the-proposed-reverse#Ga0lQPEiE7D69wRe.99

/ 2 /

As was announced on May 23, 2017, Experion is a Canadian biotech company focused on two lines of business:

1. Completion and operation of a controlled substances laboratory through an affiliate company (the “Lab Business”).

2. Obtaining a license to produce and to distribute medical cannabis products from Health Canada (the “Licensed Producer Business”) pursuant to the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”).

Experion is incorporated pursuant to the British Columbia Business Corporations Act and all of its assets are located in British Columbia. Experion currently has 13,333,333 Class “A” common shares outstanding. Experion has no other securities issued or outstanding.

The Lab Business: The Lab Business is expected to be in operation by July 2017. The Lab Business is operated by an affiliate of Experion—Northern Vine Canada Inc. The Lab Business has obtained a Controlled Substance License from Health Canada. Upon commencement of its operations, the Lab Business will become a laboratory service provider for the Canadian medical cannabis industry. As has been recently reported, unauthorized pesticides in some cannabis products have been a cause for increased focus on the safety of the Canadian medical marijuana supply by all levels of governments and end customers. The Lab Business is expected to help fill the current void in testing, and be available to licensed producers to test marijuana products. Testing is expected to include determination of chemical components and potency of products, physical testing, microbial analysis, and chemical contaminants testing.

The Licensed Producer Business: Experion is proceeding to obtain all necessary licenses and authorizations permitting it to become a licensed producer of medical marijuana pursuant to the ACMPR (the “ACMPR License”). Experion has applied to Health Canada for an ACMPR License to cultivate medical marijuana and has successfully completed the “review” stage of the Health Canada licensing process. This means that Experion received a “Confirmation of Readiness” letter from Health Canada (also known as a “ready to build” letter) in June 2016. In early June 2017, Experion expects to request its Pre-license Inspection by Health Canada.

Experion anticipates completion of construction of its state-of-the-art indoor production, secure storage and processing facility located in Mission, British Columbia (the “Mission Site”) by June 30, 2017. Upon substantial completion of construction at the Mission Site, it will be made available for the Health Canada inspection. Upon completion of a satisfactory Pre-License Inspection by Health Canada, Experion expects to be authorized to commence the cultivation of medical marijuana.

Upon receipt of its ACMPR License, Experion plans to commence the cultivation of medical-grade marijuana with a focus of growing whole plant “starter material” for wholesale distribution to licensed growers and the production and processing of dried cannabis flower for wholesale distribution. The Mission Site facility is 8,300 square feet of which approximately 2,000 square feet will be used to grow medical-grade marijuana. Experion also plans to expand its production facilities by constructing 40,000 square feet of greenhouse canopy (the “Greenhouse”), subject to Health Canada approval, for whole plant cultivation.

The above description of the Licensed Producer Business is conditional on Experion receiving its license under the ACMPR. Experion is essentially a late-stage license applicant.

As of May 31, 2017, Experion had $1,260,685 on deposit with its bank. Experion anticipates that the major expenditures during June and July 2017 will be the costs related to the Transaction and the balance of the costs related to the completion of the Mission Site facility to be used in the Licensed Producer Business. Construction of the Mission Site facility is ahead of schedule and currently below budget. Completion of the Mission Site facility is anticipated to occur by June 30, 2017, with total additional costs to be incurred to complete the facility estimated by Experion management to be approximately $290,141.

Share this post


Link to post
Share on other sites

Bad News for Canadian Marijuana Stocks:

Say Hello to Your New Competition Health Canada may be about to open the floodgates for licensed cannabis growers.

Sean Williams
Jul 17, 2017 at 9:38AM

When it comes to North America's fastest-growing industries, chances are you'd struggle to find any with a higher, more consistent growth rate than legal marijuana. And investors know it, which is a big reason some of the largest marijuana stocks have risen by 100%, 200%, or even more, over the trailing one-year period.

According to cannabis research firm ArcView, North American sales of legal pot, both recreational and medical, soared 34% in 2016 to $6.9 billion, and they're expected to grow by an average of 26% through 2021 to nearly $22 billion. This growth is expected to come from legalization of the substance -- Mexico recently legalized medical cannabis throughout the country, and eight states have legalized recreational weed in the U.S. since November 2012 -- and organic growth from states and countries where the drug is already legal. In Canada, for instance, the number of eligible medical patients has been growing at a pace of almost 10% per month, according to Health Canada.

Pot stocks face numerous challenges

But the weed landscape isn't perfect. Marijuana stocks also face a plethora of challenges each and every day.

As an example, U.S.-based cannabis companies have little or no access to basic banking services. Financial institutions in the U.S. report to the Federal Deposit Insurance Corporation, which is a federally created entity. Since marijuana is a Schedule I, and ergo illicit, substance at the federal level, banks deny financial services (even checking accounts) to pot businesses for fear of fines or criminal penalties under a strict interpretation of federal law. That means these businesses have to rely solely on cash, which is a big security concern.

Weed-based companies also get no love come tax time. Because they sell a Schedule I substance, they're disallowed from taking normal corporate income-tax deductions. Profitable marijuana companies are left to pay tax on their gross profits instead of their net profits, leaving less money to reinvest in the business.

Throughout North America, marijuana stocks are also subject to political challenges. In the U.S., industry opponents such as Attorney General Jeff Sessions stand at the ready to trample states' rights and prosecute medical-marijuana businesses. Meanwhile, conservatives in Canada's parliament are doing what they can to halt the progress of a recreational legalization bill that Prime Minister Justin Trudeau introduced earlier this year. Conservatives in Canada argue that a home-grow option in the bill would give minors easy access to cannabis, and that a lack of DUI guidelines for marijuana use make legalizing the drug dangerous.

Bad news for Canadian marijuana stocks

Well, I have news for marijuana stock investors: There's a new threat on the horizon, at least for our neighbors to the north.

In May, Health Canada, the regulatory agency that seeks to protect the medical welfare of Canada's citizens, announced that it was making a number of changes to the country's medical marijuana program. Some of these changes included eliminating the red tape associated with gaining licensing approval for production. However, the big change it announced was that it would increase the number of licensed cannabis producers. As of May 24, there were only 44 licensed producers throughout the country, but 187 applications were at the review stage. It seems unlikely that the number of licensed producers is going to quintuple overnight since not every application will be accepted, but there's a real possibility of significant near-term licensed producer growth.

Right now, Canada's biggest medical growers include Canopy Growth Corp.(NASDAQOTH:TWMJF), Aphria (NASDAQOTH:APHQF), Aurora Cannabis(NASDAQOTH:ACBFF), and the recently public MedReleaf (NASDAQOTH:MEDFF)(TSX:LEAF). This news suggests that all four will soon face a significant uptick in competition, making their expansionary efforts all the more important, with Canada tinkering with the idea of legalizing recreational weed.

Canopy Growth Corp. recently completed the acquisition of Mettrum Health, boosting its medical patient reach throughout Canada, and it also purchased 472,000 square feet of land housing and surrounding its headquarters. This should allow it to further boost its production capacity.

Meanwhile, the other three industry juggernauts have stuck to more organic methods of capacity expansion. Aphria's $100 million capital project, known as Phase IV, will boost capacity to 1 million square feet and 75,000 kilograms of cannabis annually when completed. Aurora Cannabis' Aurora Sky project is a mammoth 800,000-square-foot facility that could very well be the most automated and technologically advanced grow facility when finished. And finally, MedReleaf is using its initial public offering proceeds to expand capacity at its Bradford, Ontario facility.

A grim reality

Just how badly could this increase in competition sting the likes of Canopy Growth, Aurora Cannabis, Aphria, MedReleaf, and its peers? According to a recently released analyst note from Neil Maruoka of Canaccord Genuity, Health Canada's willingness to grant more licenses means it's unlikely that any one company will control more than 20% of cannabis supply.

Said Maruoka: "Our projections of respective market sizes remain largely unchanged, and while we remain confident this growth can be achieved, we also believe the significant increase in granted licenses is likely to create stronger competition among LPs [licensed producers]. We continue to expect that established producers with solid balance sheets, such as Canopy, Aphria, and Aurora, are likely to emerge as dominant players; however, we no longer feel it is reasonable to assume that any one LP can capture over 20% share of a likely increasingly crowded market."

Maruoka and his firm wound up lowering their respective market share estimates for leader Canopy Growth to 15% of the recreational market (assuming approval) and 12% of the medical market, down from an initial share forecast of 21% and 17.5%, respectively. Canaccord also expects Aurora Cannabis to be second with 10% of recreational and medical market share, and Aphria third with a 9% recreational and 7.5% medical share.

Not surprisingly, Maruoka and his firm also lowered their price targets for a half-dozen marijuana stocks and reduced their rating on five of six companies. As a sign of how far Aphria has fallen from its 52-week high, it was actually upgraded even though its share-price target was modestly lowered.

All bets are off

Despite its consistently strong growth rate, there simply aren't any guarantees at this point that success awaits marijuana stocks. There have been some encouraging early signs of profitability, albeit minimal, from companies such as Canopy Growth, Aphria, and MedReleaf, but at the same time, there aren't any assurances that Trudeau can get his recreational-cannabis legislation signed into law. After all, he's been pushing for legalization for years without any progress, so what's to say with any certainty that it happens now?

With competition increasing, the future uncertain, and most marijuana stocks either unprofitable or valued at nosebleed P/E ratios, your best bet for the time being is to steer clear of the industry.

Marijuana stocks are overhyped: 10 better buys for you now
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and marijuana stocks were noticeably absent! That's right -- they think these 10 stocks are better buys.

Learn more

*Stock Advisor returns as of July 6, 2017


Read more at http://www.stockhouse.com/companies/bullboard#1f85FOCu2cJa0grg.99

Share this post


Link to post
Share on other sites

Canada's main Cannabis-related, medical growers

 

" We continue to expect that established producers with solid balance sheets, such as Canopy, Aphria, and Aurora,

are likely to emerge as dominant players;" - Canaccord

 

Canada's biggest medical growers include

Canopy Growth Corp.(NASDAQOTH:TWMJF),

Aphria (NASDAQOTH:APHQF),

Aurora Cannabis (NASDAQOTH:ACBFF), and the recently public

MedReleaf (NASDAQOTH:MEDFF)(TSX:LEAF). T

==================

 

Canopy Growth Corp. WEED.T (NASDAQOTH:TWMJF) ... all-data : 2yrs : 12mos :

7IFWubL.gif

 

Aphria Inc. APH (NASDAQOTH:APHQF), ... all-data : 2yrs : 12mos :

WZtGSfV.gif

 

Aurora Cannabis ACB (NASDAQOTH:ACBFF), ... all-data : 2yrs : 12mos :

QRxpKzX.gif

 

and the recently public :

MedReleaf (NASDAQOTH:MEDFF)(TSX:LEAF). ... all-data : 2yrs : 12mos :

8un5Lrw.gif

Share this post


Link to post
Share on other sites

Dear Reader,

Justin Spittler, editor of the Casey Daily Dispatch, here.

For the last few months, I’ve been pounding the pavement on the massive profit potential in pot stocks.

I’ve shown you how Doug made 1,900% gains on a penny pot stock.

How the best of these pot stocks averaged 29,000% gains.

I even told you about three pot stocks to buy right now.

=====

 

SPLITS:

Morro Bay / VIR – Split 10-1 in May, then 3.603 for one last week

Share this post


Link to post
Share on other sites

Marijuana real estate is big business…

And the world's first publicly traded REIT for pot gives you the chance to cash in big… without buying, selling, or investing in real estate yourself.

Here's how it works…

image001.png

Landlords renting to growers make up to 260% more revenue.

Farmers bring in 10 times more money.

But the high rates growers pay kills cash flow.

This marijuana REIT is buying up the most valuable land in the world. And leasing it back to growers.

Growers get the cash they need to expand.

And the REIT cashes in big by charging premium rates for the land.

If you buy stock in this company, you instantly own some of the most profitable real estate on earth.

And because this is a REIT, it must pay out at least 90% of its taxable income as dividends.

It went public in December 2016.And it's already paying out dividends on profits.

And this is just one of 3 pot stocks we see exploding soon.

While nothing in the market is guaranteed, we're expecting a new law to revolutionize the marijuana industry.

All indications are that the law will move forward by October 31.

And if it does, these 3 marijuana stocks could go through the roof. So now is the perfect time to take advantage of marijuana mania. Get the whole story here.

To your personal pot profits,

jspittler-175px.png
Justin Spittler
Editor, Casey Daily Dispatch

Share this post


Link to post
Share on other sites

www.indica.fund

Investment Objective

Achieve long-term capital appreciation by investing in companies operating in the North American cannabis industry.

The Fund’s investment focus will be on low risk ancillary services, brands and consumer applications that underlie and support the legalized cannabis industry. The Fund will not have direct invest- ment exposure in companies that are growers or distributors of the cannabis plant itself.

The Investment Advisor

Nesta Holding Co. Ltd is a Canadian based private equity rm investing in the North American cannabis industry. The company was founded in 2015 by Chuck Ri ci the former founder and CEO of ...

Canopy Growth Corp. (TSX:CGC / WEED) ... update

xx

Since its inception, Nesta has grown its AUM by nearly 300% focus- ing on scalable, high margin ancillary opportunities servicing the cannabis industry: digital services, consumer application technolo- gy, brand IP as well as alternative nancing vehicles – opportunities that leverage the tremendous growth of the North American canna- bis industry without the regulatory risk.

The Market Opportunity

ArcView Market Research projects the legalized North American cannabis industry will top US$22.6 billion by 2021, growing at a 27% annual CAGR. Still, large institutional investors are reluctant to invest due to acute regulatory uncertainty, despite the growth trajectory.

The high customer demand for legal cannabis combined with the arti cially restricted availability to capital to fund consumer brands and applications creates a very large market opportunity for Nesta.

Target Investments

One Web Services: the largest price comparison web-site and mo- bile app for the U.S. cannabis industry. (www.wikileaf.com)

Feather Co: manufacturer of pre- lled disposable vaporizers target- ing recreationally legal states in the U.S. (www.feather.co)

Kush Bottles: Leading wholesaler of marijuana & cannabis compli- ant packaging. (www.kushbottles.com)

Exit Strategy

The Fund’s investment returns will be largely achieved through capital growth. Thus, a key to any new investment appraisal will be the potential for successful realization of value within 3-5 years from the date of initial investment. With anticipated enterprise values on exit of between $30m and $100m, the investee companies will be ex- pected to provide realistic secondary/buy-out opportunities as well as the prospect of an IPO, depending on the market environment at the time.

 

Management

Chuck Ri ci: Chairman & CEO of Nesta Holding Co. Ltd., previously founder and CEO of Canopy Growth Corp., North America’s largest cannabis company

Manoj Hippola: Managing Director and CIO of Nesta Holding Co. Ltd; previously CFO with a publicly listed U.S. company

Nigel Eyles Managing Director, Nesta Europe S.A. previously in senior institutional sales roles with UBS and Lehman Brothers

Share this post


Link to post
Share on other sites

Viridium - Stock price history still matters... apparently

VIR... update : 2yrs :

thE6RNw.gif

Share this post


Link to post
Share on other sites

PicsArt_08-24-02-43-28.jpg

Canadian Marijuana index

Share this post


Link to post
Share on other sites

Canopy Growth, world’s largest pot company, lost $1 billion in three months MarketWatch

Stock falls 10% in late trading after elimination of C$1.18 billion in warrants related to Constellation Brands investment leads to earnings miss

MW-HL702_Canopy_20190619111841_ZH.jpg?uuBloomberg News/Landov
Analysts surveyed by FactSet had estimated fiscal first-quarter adjusted losses of C$0.38 a share on revenue of C$111.9 million

Canopy Growth Corp. reported a C$1.28 billion quarterly loss late Wednesday and missed analyst revenue estimates for revenue, sending shares down 10% in after-hours trading.

The world’s largest cannabis company by market value, Canopy Growth CGC, -6.64% WEED, -5.76%  reported fiscal first-quarter net losses of C$1.28 billion, or C$3.70 a share, compared with losses of C$91 million, or 40 cents a share, in the year-ago period. The more than $1 billion loss was due to the company extinguishing warrants related to the Constellation Brands Inc. STZ, -1.61%  investment.

Canopy Growth fired co-Chief Executive Bruce Linton not long after its previous earnings report, amid reports of unhappiness at Constellation with continuing large losses. CEO Mark Zekulin has remained at the helm of the company, but has said he expects to exit once a new leader is found.

Net revenue rose to C$90.5 million from C$25.9 million in the year-ago period, excluding excise taxes. Of that revenue, Canopy said that C$50.4 million was Canadian recreational business-to-business, C$10.6 was direct to consumer and C$13.1 million was medical cannabis sales. Canopy also brought in $10.5 million in international cannabis revenue.

Analysts surveyed by FactSet had estimated fiscal first quarter adjusted losses of C$0.38 a share on revenue of C$111.9 million. Canopy did not provide any per-share adjusted-earnings information.

Share this post


Link to post
Share on other sites

I am happy I dumped this shortly after the foray into Marijuana labs

VIR > EXP / EXPERION Holdings ... all-data : vs-WEED : 5-yr : 2-yr : 12mo ::

VoNsOPA.gif

: EXP-vs-WEED :

2olCLPP.gif

“Experion Holdings Ltd.” (TSX-V: EXP).

June 10, 2019 (Source) – Viridium Pacific Group Ltd. (the ”Company”) (TSX-V: VIR ) is pleased to announce that the Company has changed its name from “Viridium Pacific Group Ltd.” to “Experion Holdings Ltd.” (TSX-V: EXP).The Company’s shareholders approved the name change at a special meeting of shareholders held on May 31, 2019. Effective on market opening on June 10, 2019, the common shares of the Company will commence trading on the TSX Venture Exchange under the Company’s new name, Experion Holdings Ltd., and under the trading symbol ”EXP”. With the new change in name, there is no consolidation of capital and the CUSIP Number will be 30219B109.

Mr. Jay Garnett, Chief Executive Officer, commented, “We are excited to have both our Licence and corporate entity under Experion. Having a focused brand strategy, under one corporate brand, will bring alignment to the market and our shareholders. In addition, it will allow us to better communicate our value proposition as we work to unlock value and communicate our accomplishments to the market and stakeholders.”

No action is required to be taken by current shareholders in connection with the change in name and no change has been made to Experion Holdings Ltd. share capital.

About Experion Holdings Ltd.

Experion Holdings Ltd. is the parent company of Experion Biotechnologies Inc., a Health Canada licensed cultivator and processor of Cannabis, based in Mission, BC; and EFX Laboratories Inc., a medical products production and clinical research company based in Calgary, AB.

Experion Holdings Ltd. is invested in a portfolio of products to address a wide spectrum of consumer needs’ including Medical, Adult-use, and Wellness and Therapeutic products.

Share this post


Link to post
Share on other sites

Experion Holdings Ltd  Update

Recent Bulletins News ReleasesIn The NewsOther
Date ET Symbol Price Type Headline
2019-08-06 09:51 C:EXP 0.215 News Release Experion has claim for 10.27 M shares dismissed
2019-07-25 11:08 C:EXP 0.24 News Release Experion's chairman McWatters dies
2019-07-24 13:19 C:EXP 0.24 News Release Experion files Q2 financials, talks recent work
2019-07-24 12:23 C:EXP 0.24 SEDAR Interim Financial Statements SEDAR Interim Financial Statements
2019-07-24 12:23 C:EXP 0.24 SEDAR MD & A SEDAR MD & A
VANCOUVER, British Columbia, July 24, 2019 (FSCwire) Experion Holdings Ltd. (“Experion” ...

Financials

Experion has now filed its Q2 2019 consolidated interim financial statements, and management discussion and analysis for the six months ended May 31, 2019 on SEDAR.

Business Update – Domestic and International Market Development

Domestic Market:

In January 2019, the Company begun to sell clones to newly licensed Standard Cultivators looking for quality genetics to launch their cultivation process. The sales expand Experion’s product line with clones exhibiting the desired specifications and attributes for both the medical and Adult-use market.  Under the Cannabis Act, a cultivation license can sell product to other licensed facilities fostering new business to business relationships and the ability to create quick strategic partnerships as the market becomes established. All starting materials sold as clones to other cultivators have a flower buy back program with Experion. As well, Experion can also sell clones for medical purposes to qualified individuals as a licensed medical supplier.

International Market:

In June 2019, Experion signed a non-binding letter of intent (“LOI”) with a Polish import and distribution company to export medical flower products to Poland. Under the executed LOI, Experion will export medical flower products to Poland for scientific purposes enabling the Polish company to test and develop Experion’s flower products. After the successful completion of this testing, Experion will export its flower products to Poland for consumer medical use. Experion is currently working towards European Union Good Manufacturing Practice (“GMP”) certification of its Mission facility in British Columbia, which will allow the export of cannabis to the EU for medical consumption. Experion is actively seeking export opportunities in Europe and plans to continue to build its international distribution chain.

Corporate Update

During the current period, Experion continued to strengthen is executive team and appointed Kamini Hitkari to the position of Chief Financial Officer. The Company also hired Judy-Ann Pottinger to provide comprehensive investor relations and corporate communications services.

On June 10, 2019, Experion changed its name from Viridium Pacific Group Ltd. to Experion Holdings Ltd. and changed its trading symbol from “VIR” to “EXP” on the TSXV. A focused brand strategy, under one corporate brand, will bring alignment to the market and our shareholders.

Share this post


Link to post
Share on other sites

FIRE dropped in price. Cv.Debs too

FIRE ... all-data / Last: C$0.90 - 0.01

NEBB3Qa.gif

FIRE.DB ... Last : $76

yNv0U9k.png

==

Risk ——: UnderV / Company -------- : Coupon : Maturity : Db.Price: Y.T.M.
Mod.  :
AD.DB       : 9.53% / Alaris Royalty------: 5.50% : 30-Jun-24 : $  95.75 : 6.54%:
Spec.
FIRE.DB  : 23.6% / SupremeCannabis 6.00% :  19-Oct-21 : $  85.00 : 14.4%
JE.DB.D  : 45.2% / Just Energy----------: 6.75% : 31-Mar-23 : $  67.50 : 19.8%

SUPREME CANNABIS ANNOUNCES Q4 AND 2019 FISCAL YEAR END FINANCIAL RESULTS

The Supreme Cannabis Company Inc. has released its financial and operating results for the fourth quarter and fiscal year ended June 30, 2019.

"We end fiscal 2019 as one of the few Canadian cannabis businesses building sustainable operations and valuable brands, reporting $3.2-million in adjusted EBITDA [net income (loss) excluding fair value changes on growth of biological assets, realized fair value changes on inventory sold or impaired, amortization of property, plant and equipment, and intangible assets, share-based payments, finance expense, loss on disposal of property, plant and equipment, unrealized gains or losses on investments, and income taxes] (1) for the fourth quarter," said Navdeep Dhaliwal, chief executive officer of Supreme Cannabis. "Our positive adjusted EBITDA and significant revenue growth in the fourth quarter reflects the rapid scale of our 7Acres business and continued strong sales pricing for our brands from the provinces as we transition our premium supply to recreational sales channels.

"With strong confidence in our core business, we began fiscal 2020 with two accretive acquisitions that expanded our addressable markets, provided valuable licensed operating assets and focused expertise," Mr. Dhaliwal added. "As we integrate these businesses and realize further efficiencies from our scaled 7Acres operations, we expect all of our brands to meaningfully contribute to the revenue we have forecasted for fiscal 2020. Amidst the noise of this new marketplace, Supreme Cannabis has taken a strategic and disciplined approach to develop a focused business with clear pillars: best-in-class infrastructure, top consumer brands, advanced intellectual property, and high-impact and capital-light exposure to developing international markets."

               FOURTH QUARTER AND FISCAL YEAR-END SELECT FINANCIAL AND OPERATIONAL RESULTS
                                          ($ thousands) 

                                                    Three months ended                     Year ended                
                                             June 30, 2019     June 30, 2018     June 30, 2019     June 30, 2018

Net revenue                                        $19,005            $3,545           $41,833            $8,855
Operating expenses                                  11,564             5,114            38,713            15,866
Net (loss) after taxes                                (421)              234           (14,497)           (7,347)
Basic and diluted (loss) per common share            (0.00)            (0.00)            (0.05)            (0.03)
Adjusted EBITDA (1)                                  3,195            (1,641)           (4,452)           (6,964)

Brands

Supreme Cannabis's core recreational flower brand, 7Acres, accounted for the company's marked increase in revenue, growing 443 per cent year over year from $3.5-million in fourth quarter 2018 to $19-million in fourth quarter 2019 and 90 per cent quarter over quarter from $10-million in third quarter 2019.

Outlook

Supreme Cannabis believes that the company is well positioned to take significant steps forward in fiscal 2020, including:

  • Expected net revenue of between $150-million and $180-million;
  • Expected positive adjusted EBITDA (1) on aggregate over the course of the year;
  • 7Acres to complete its transition from a wholesale business to premium consumer brand by third quarter fiscal 2020, with complete in-house packaging capabilities for all flower products under the 7Acres brand;
  • Pursuing non-dilutive financing with Tier 1 banks and other lenders to provide financial flexibility for future growth initiatives;
  • Fully financed to execute on all planned initiatives.

> https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aFIRE-2810691&symbol=FIRE&region=C

Share this post


Link to post
Share on other sites

Canadian Cannabis stocks under pressure

EXP-etc ... update : +etc : 10d / Last: C$0.15, WEED: $0.00, FIRE: $0.90

4VlsRoP.gif

4 days ago - 
Weed stocks fell on Thursday after Hexo, a Canadian cannabis company,
+ withdrew its full-year revenue guidance at an investor event Thursday, citing market uncertainty.
Shares of Hexo fell as much as 26% on the news.
The stocks of Tilray (TLRY), Aurora Cannabis (ACB.t), Canopy Growth (CGC), and Cronos (CRON) also slipped.
The weed industry is facing increased uncertainty and the environment will likely continue to be difficult,
according to W. Andrew Carter, an analyst at Stifel.

Share this post


Link to post
Share on other sites

Cannabis Extracts Will Propel Industry’s Rise

Longtime readers will remember the first time I put cannabis investing on your radar.

That was over two years ago.

At the time, there were only a couple dozen publicly traded cannabis companies. Today, there are over 300.

New ones seem to be popping up each week. Others are merely adding “cannabis” or cannabis-related words to their company names to tap into the green gold rush.

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this  

×